News

Under the agreement, NBE and Sotio will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products will be based on

The compound, named RXC005, has the potential to treat the majority of patients suffering from Chronic Lymphocytic Leukaemia (CLL), including those who become resistant to the increasingly used

The study enrolled 540 subjects who received letermovir once daily either in an oral tablet or intravenous formulation. Therapy was begun as early as the same day as

LARTRUVO's indication is approved under Accelerated Approval, and is based on data from the Phase 2 portion of the pivotal JGDG trial. Continued approval for this indication may

LIMT HDV is a 30-patient study designed to evaluate the safety, tolerability and efficacy of two dose levels of Lambda after 48 weeks of treatment.  LIMT HDV is

SOBI003 will be included in the EU Community Register of Orphan Medicinal Products. MPS IIIA or Sanfilippo A syndrome is an inherited systemic lysosomal storage disease with a

It is the second collaboration between both the parties focusing on dengue. The first one was related to the development of a botanical drug to treat dengue. The

Life sciences-focused venture capital firm Medicxi Ventures has agreed to invest up to €9m in Mavalon. Mavalon is developing an orally available small molecule able to induce Glial

ONIVYDE is the first and only approved treatment option for this patient population. With this approval, Shire is authorized to market ONIVYDE in the 28 Member States of